The
global cancer microbiome sequencing market is anticipated to observe impressive
growth during the forecast period, 2023-2027. The major factors include growing
occurrences of cancer and increasing emphasis on the microbiome’s potential in
the field of cancer are fueling the growth of the market. Microbiomes are the community of microorganisms that grow or exist on an
environment such as saliva, skin layers, oral mucosa of human body and the
gastrointestinal tract. Microbiome sequencing is a valuable tool which is used
to study and analyze the microbes groups located in or out of the human body to
have the better understanding of human microbes. The main aim of microbiome
research study is to understand the role and function of microbes in human
health and disease. The other factors supporting the market’s growth are, decreasing cost of sequencing, rise in R&D
activities, exponential rise in the number of cancer cases worldwide,
increasing number of clinical trials, rise in development of novel diagnostic tools
based on microbiome for supporting physicians, increasing investments by
biotechnology companies, rise in demand for microbiome sequencing services for
diagnosis and early detection of the diseases, rise in world population, growing
awareness of the use of microbiome sequencing technology, rise in the
healthcare expenditure, rising interest of researchers in understanding the
role of microbiome in human health and disease, and immense potential for
emerging submarkets.
Rising
Prevalence of Cancer supports the Market Growth
Growing
incidences of cancer such as lung, cervical, breast, skin, throat, and others
are augmenting the growth of the market. According to WHO, in 2020, cancer
is a major cause of death across the world, reporting for approximately 10
million deaths, or about one in six deaths. The most common cancers are
lung, colon and rectum, prostate cancers, and breast. There is a surge in number
of cases suffering from cancer caused due to consumption of alcohol, tobacco
use, unhealthy eating choices, and sedentary lifestyle. Therefore, need for
cancer microbiome sequencing is rising, which in turn, bolster the growth of
the market. As per WHO, many cancers can be treated effectively if detected
in an early stage.
Increasing
Emphasis by Researchers on the Microbiome’s Potential and Rising Support from
Biotechnology Companies.
The
rising focus on the microbiome’s potential to diagnose, and prevent various
cancers is fueling the growth of the market. Various researchers are studying
and researching the microbiome’s potential in the field of cancers. Researchers
are being supported by biotech companies to unravel insights pertaining to
microbiome’s influence on cancer progression and manifestation. Furthermore,
the development of cancer microbiome sequencing services and products have
aided the research community to create effective strategies for discovering
novel cancer biomarkers allied with the microbiome, which could be used for the
development of cancer microbiome sequencing products for clinical use.
Download Free Sample Report
Market Segmentation
The
global cancer microbiome sequencing market is segmented into
component, technology, application, end
user, and
company. Based on
component, the market is divided into kits & assays, software, and services.
Based on technology, the market is divided into next generation sequencing and polymerase chain reaction. Based on application, the
market is divided into translational research and clinical diagnostics. Based
on end user, the market is divided into biotechnology & pharmaceutical
companies, academic & research institutions, hospitals & clinics, and
others. In
terms of country, the United States is expected to be a lucrative market in the
forecast period due rising incidences of cancer and rise in R&D activities in
the country.
Market Players
Illumina, Inc., Eurofins
Scientific SE, QIAGEN NV, Thermo Fischer Scientific, Inc., Oxford Nanopore
Technologies plc., OraSure Technologies, Inc., Pacific Biosciences of
California, Inc., Psomagen, Inc, Prescient Medicine Holdings, Inc., and Micronoma
Inc. are some of the
leading companies operating in the market.
|
Attribute
|
Details
|
|
Base Year
|
2021
|
|
Historic Data
|
2017 – 2020
|
|
Estimated Year
|
2022
|
|
Forecast Period
|
2023 – 2027
|
|
Quantitative Units
|
Revenue in USD Million, Volume Units and
CAGR for 2017-2021 and 2022-2027
|
|
Report coverage
|
Revenue forecast, Volume forecast company share, competitive
landscape, growth factors, and trends
|
|
Segments covered
|
·
Component
·
Technology
·
Application
·
End User
·
Company
|
|
Regional scope
|
North America; Asia Pacific; Europe & CIS; South America;
Middle East & Africa
|
|
Country scope
|
United States; Canada; Mexico; China;
India; Japan; South Korea; Germany; France; United Kingdom; Spain; Italy; Brazil;
Argentina; Colombia; South Africa; UAE; Saudi Arabia; South Africa; Australia;
Turkey; Egypt;
|
|
Key companies profiled
|
Illumina, Inc., Eurofins Scientific SE, QIAGEN NV, Thermo
Fischer Scientific, Inc., Oxford Nanopore Technologies plc., OraSure
Technologies, Inc., Pacific Biosciences of California, Inc., Psomagen, Inc,
Prescient Medicine Holdings, Inc., and Micronoma Inc.
|
|
Customization scope
|
10% free report customization with
purchase. Addition or alteration to country, regional & segment scope.
|
|
Pricing and purchase options
|
Avail customized purchase options to meet your exact research
needs. Explore purchase options
|
|
Delivery Format
|
PDF and Excel through Email (We can also provide the editable
version of the report in PPT/Word format on special request)
|
Report Scope:
In this report, global cancer
microbiome sequencing market has been segmented into following categories, in
addition to the industry trends which have also been detailed below:
·
Cancer Microbiome Sequencing Market, By Component:
o
Kits
& Assays
o
Software
o
Services
·
Cancer Microbiome Sequencing Market, By Technology:
o
Next
Generation Sequencing
o
Polymerase
Chain Reaction
·
Cancer Microbiome Sequencing Market, By Application:
o
Translational
Research
o
Clinical
Diagnostics
·
Cancer Microbiome Sequencing Market, By End User:
o
Biotechnology
& Pharmaceutical Companies,
o
Academic
& Research Institutions
o
Hospitals
& Clinics
o
Others
·
Cancer Microbiome
Sequencing Market, By Region:
- North America
- United States
- Canada
- Mexico
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- Europe & CIS
- Germany
- France
- United Kingdom
- Spain
- Italy
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
§
South
Africa
§
Saudi
Arabia
§
UAE
§
Turkey
§
Egypt
Competitive Landscape
Company Profiles: Detailed analysis of the
major companies present in Global Cancer Microbiome Sequencing Market
Available Customizations:
With the given market data, TechSci
Research offers customizations according to a company’s specific needs. The following
customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to
five).
Cancer Microbiome Sequencing Market is an upcoming report to be released
soon. If you wish an early delivery of this report or want to confirm the date
of release, please contact us at [email protected]